Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Total protein extraction from cultured cells for use in electrophoresis and western blotting.

Wang KK, Posner A, Hajimohammadreza I.

Biotechniques. 1996 Apr;20(4):662-8.

PMID:
8800687
2.
3.
4.

Neuroprotection with a calpain inhibitor in a model of focal cerebral ischemia.

Hong SC, Goto Y, Lanzino G, Soleau S, Kassell NF, Lee KS.

Stroke. 1994 Mar;25(3):663-9.

PMID:
8128523
5.

Calpain: new perspectives in molecular diversity and physiological-pathological involvement.

Saido TC, Sorimachi H, Suzuki K.

FASEB J. 1994 Aug;8(11):814-22. Review.

PMID:
8070630
7.

Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage.

Bartus RT, Baker KL, Heiser AD, Sawyer SD, Dean RL, Elliott PJ, Straub JA.

J Cereb Blood Flow Metab. 1994 Jul;14(4):537-44.

PMID:
8014200
8.

Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intra-arterial administration.

Bartus RT, Hayward NJ, Elliott PJ, Sawyer SD, Baker KL, Dean RL, Akiyama A, Straub JA, Harbeson SL, Li Z, et al.

Stroke. 1994 Nov;25(11):2265-70.

PMID:
7974554
9.

Excitatory amino acids as a final common pathway for neurologic disorders.

Lipton SA, Rosenberg PA.

N Engl J Med. 1994 Mar 3;330(9):613-22. Review. No abstract available.

PMID:
7905600
10.

Ca2+ entry via AMPA/KA receptors and excitotoxicity in cultured cerebellar Purkinje cells.

Brorson JR, Manzolillo PA, Miller RJ.

J Neurosci. 1994 Jan;14(1):187-97.

11.

Calpain inhibition: an overview of its therapeutic potential.

Wang KK, Yuen PW.

Trends Pharmacol Sci. 1994 Nov;15(11):412-9. Review.

PMID:
7855906
12.

Casein zymography: a method to study mu-calpain, m-calpain, and their inhibitory agents.

Raser KJ, Posner A, Wang KK.

Arch Biochem Biophys. 1995 May 10;319(1):211-6.

PMID:
7771786
13.
14.

Attenuation of AMPA-induced neurotoxicity by a calpain inhibitor.

Caner H, Collins JL, Harris SM, Kassell NF, Lee KS.

Brain Res. 1993 Apr 2;607(1-2):354-6.

PMID:
7683243
15.

Time-related neuronal changes following middle cerebral artery occlusion: implications for therapeutic intervention and the role of calpain.

Bartus RT, Dean RL, Cavanaugh K, Eveleth D, Carriero DL, Lynch G.

J Cereb Blood Flow Metab. 1995 Nov;15(6):969-79.

PMID:
7593358
16.

Induction of calpain-mediated spectrin fragments by pathogenic treatments in long-term hippocampal slices.

Bahr BA, Tiriveedhi S, Park GY, Lynch G.

J Pharmacol Exp Ther. 1995 May;273(2):902-8.

PMID:
7538583
17.

A specific inhibitor of calcium/calmodulin-dependent protein kinase-II provides neuroprotection against NMDA- and hypoxia/hypoglycemia-induced cell death.

Hajimohammadreza I, Probert AW, Coughenour LL, Borosky SA, Marcoux FW, Boxer PA, Wang KK.

J Neurosci. 1995 May;15(5 Pt 2):4093-101.

18.

Brain fodrin: substrate for calpain I, an endogenous calcium-activated protease.

Siman R, Baudry M, Lynch G.

Proc Natl Acad Sci U S A. 1984 Jun;81(11):3572-6.

20.

Supplemental Content

Support Center